Penumbra, Inc. (PEN) Earnings Call Transcript & Summary

February 23, 2021

New York Stock Exchange US Health Care Health Care Equipment and Supplies earnings 58 min

Earnings Call Speaker Segments

Jee Hamlyn-Harris

executive
#1

Thanks, operator, and I'm glad all of you could join us today as we review Penumbra's results for the fourth quarter and year-end 2020. The press release is available, and with it you'll find the financial tables, including the reconciliation from GAAP to non-GAAP, located on our website at www.penumbrainc.com under the Investors tab. During this call, we will be providing forward-looking statements in accordance with the safe harbor protections of the Private Securities Litigation Reform Act of 1995, and these statements will address our financial performance, commercialization efforts, clinical trials, regulatory status, quality compliance and business trends. Since a number of risks and unknowns exist — including the ones we list in our 10-K covering the year that closed on December 31, 2020, set to go to the SEC on February 23, 2021 — the real outcomes may end up substantially different from anything those forward-looking statements claim or suggest. We'd advise you not to put too much weight on these forward-looking statements. We also suggest you look at our periodic filings with the SEC, including the 10-K we mentioned earlier, to get a fuller picture of these factors and other risks that could affect our future results or the market price of our stock — among them, though not limited to, how the COVID-19 pandemic has impacted our business, results of operations and financial condition. Penumbra accepts no obligation to update or revise our forward-looking statements because of new information, future events, developments or anything else. On this call, some financial measures are presented on a non-GAAP basis. Details bridging GAAP and non-GAAP figures appear in the press release we've made available. Today's prepared remarks should take roughly 20 minutes. A business update will come from Penumbra's Chairman and CEO, Adam Elsesser. After that, our Chief Financial Officer, Maggie Yuen, will walk through fourth quarter and full year financial results. Then Jason Mills, Executive Vice President of Strategy, will cover our 2021 guidance. I'll now hand things over to Adam Elsesser.

Adam Elsesser

executive
#2

Thanks, Jee, and good afternoon to everyone. I appreciate you being on the call for Penumbra's conference call covering the fourth quarter and year-end of 2020. Revenue across all operations during Q4 came to $166.9 million, which is up 14.9% versus the same period a year earlier as reported, and 13.7% on a constant currency basis — making it the second record-setting quarter in a row for Penumbra. That figure also reflected a $5.8 million hit to revenue tied to the mid-December recall of JET 7 XTRA FLEX. If you set aside that onetime effect, non-GAAP revenue for Q4 climbed 18.9%, reaching $172.7 million. Turning to the whole of 2020, annual revenue totaled $560.4 million, a gain of 2.4% compared with all of 2019. Once the onetime recall impact is excluded, non-GAAP annual revenue rose 3.4% versus 2019, hitting $566.2 million. Maggie is going to walk through the financials in more depth, along with specifics about our balance sheet, when she speaks. In my prepared comments today, I plan to cover 3 subjects. First, I'll touch briefly on the innovation culture here that has made it possible to build out our extensive product portfolio. After that, I'll bring you up to date on what's happening specifically within vascular, neuro and virtual reality. Second, I'll cover how far we've come in markets outside the United States since we last spoke, China included. And third, I'll speak to the difficulties everyone encountered across 2020 and into early 2021 because of the pandemic, plus what we expect its effects to be; at Penumbra we've established a deliberate structure and culture that lets us create and keep pushing forward on products that truly matter, even while the company expands. For close to 17 years, this capacity for ongoing innovation has been guided by a sizable group of deeply talented and driven individuals, our Pengineers among them, who are united in their dedication to tackling tough problems in health care, and that has played a key role in building our extensive product portfolio. The numbers we posted this quarter demonstrate that our products are helping more patients than at any prior point, and yet what keeps motivating us daily is how many patients remain beyond our reach. Within the United States by itself, we estimate that roughly 80% of neurovascular thrombectomy patients, more than 90% of vascular thrombectomy patients and virtually 100% of patients for whom our REAL VR technology could work may someday join the ranks of those we're able to assist using the products we currently offer. Let's begin with vascular, which during Q4 became our biggest business for the first time. Once again, our Lightning products powered robust vascular growth. As a matter of fact, our patented Lightning technology now sits inside products being used to treat patients in the venous as well as arterial areas, through Lightning 12 and, as of now, Lightning 7, which I'll get to in a moment. Lightning 12 keeps delivering outstanding results when it comes to clearing blood clot from veins and pulmonary arteries in single sessions. In Q4, Lightning 12 was granted an FDA indication for treating pulmonary embolism, or PE. Also, we shared news about teaming up with RapidAI so that their advanced AI technology can be applied beyond stroke to PE. From the first discussions we've had with pulmonary embolism response teams—PER teams at hospitals—there's substantial enthusiasm and a real need to make communication and decision-making smoother in PE cases, so that more patients can be helped and helped more quickly. When it comes to venous and pulmonary thrombectomy, Lightning 12 has only begun to tap what's possible, despite the fact that adoption and feedback from physicians since it launched in the third quarter has been remarkable. Over the past month, we began the first evaluation cases for Lightning 7, and those have gone extremely well; we anticipate a complete launch in late March. Our view is that Lightning 7 can deliver meaningful gains for divisions that treat patients with clots in their arteries, offering advantages comparable to what Lightning 12 provides—what Lightning 12 is delivering on the venous side. Beyond that, CAT RX, which is our coronary product, keeps helping a growing number of patients with coronary clot—a U.S. population we estimate is roughly equal in size to the U.S. ischemic stroke patients who qualify for mechanical thrombectomy annually. Looking across our whole vascular business, which includes peripheral embolization—another area that had a record quarter—we are set up for lasting growth over many years ahead. Let me now move to our neuro business. In Q4, we introduced BMX96, among the most innovative access products we have. Compared with our Neuron MAX guide catheter, BMX96's outer diameter is a bit smaller, yet thanks to our novel technology we were able to increase the inner diameter even further, from 0.088 to 0.096 inches. That creates more space within the guide catheter for maneuvering the other catheters involved in the procedure; physicians have responded very positively, not only for stroke cases but across all kinds of neurovascular cases. Turning to the stroke portion of the business: after the recall of JET 7 XTRA FLEX, certain stroke physicians moved straight to our ACE68 or JET 7 standard tip, while others used the chance to test other reperfusion catheters. After that trialing, a number of those physicians are returning to either ACE68 or JET 7 standard tip as their main reperfusion catheter; actually, given both the demand for exchanges related to the recall and current demand, we are dealing with a back-order situation for the JET 7 standard tip, which we expect to clear within the next month. Along with the remainder of our portfolio, these products will keep playing a key role in many stroke cases until later this year, when we update our catheters. Furthermore, we stay highly optimistic about our future innovation, which we hope will deliver even better solutions to our physician customers. For the growth of U.S., 2020 was obviously a difficult year. When it comes to stroke procedures, the main reason for the drop was COVID, but that pushes us to try even harder so we can treat a greater number of stroke patients successfully. We keep reminding ourselves how massive the expense is from the disability that follows a stroke — it devastates patients and places an immense financial weight on our health care system, running into billions and billions of dollars. It's going to take a while, but we think that because of these factors, the market will return to growth eventually. Let's turn now to the newest area for our products, virtual reality, or VR. Over the long term, VR is where we believe we can assist the largest number of patients. Our REAL Immersive VR System is proprietary technology built specifically to serve as a platform for health care applications, engineered from the ground up to provide creative applications purpose-built for medical conditions affecting millions of patients. Our vision for REAL has in fact broadened during the past year. To start with, there's a big opportunity for us to help a great many patients requiring some type of rehabilitation through applications tailor-made for patients working with their physical or occupational therapists, not just in the clinic, but also virtually while the patient is at home.

Adam Elsesser

executive
#3

When it comes to REAL, this rehab chance covers individuals healing from stroke, cardiac rehab, orthopedic rehab, movement disorders, traumatic brain injury and additional conditions; we also feel it matters to provide a wide range of applications aimed at assisting patients dealing with chronic pain, mental health, stress and anxiety and memory loss, among others. There's already substantial clinical evidence regarding the advantages virtual reality delivers for rehab as well as mental health applications, and our plan is to expand upon that data, collaborating with a number of the top VR health care experts globally to create applications and clinical evidence for the REAL platform; we completely acknowledge that plenty of unknowns are still present, and we have much to demonstrate when it comes to the REAL platform, yet we firmly believe that our work with the REAL platform genuinely matters and could assist a large number of individuals. Now let me bring you up to date on our international business, which did well during the quarter. To start, I want to share company updates regarding China. In the fourth quarter, we entered a new multifaceted agreement with Genesis MedTech Group, which merged with Hua Medtech, our previous partner, making it, in our view, the biggest domestic company in China's neurovascular space. Our initial collaboration is a multiyear, fixed-term, strategic partnership covering 5 products: ACE68, ACE60, 3MAX, Neuron MAX, 088 and JET D; and every product generates 3 separate revenue streams: licensing, royalties and product distribution, for which we have solid visibility. We're thrilled to be partnering with Genesis since they share our dedication to patients, and we believe they possess the capacity and expertise to deliver these important technologies to patients in China. We're also enthusiastic about upcoming opportunities for Penumbra in Japan. Although 2020 proved a difficult year for us in Japan, because of COVID reimbursement changes and in the end the JET 7 XTRA FLEX recall, we identify many opportunities for growth in the region, not just in our existing stroke and vascular embolization business, but in vascular thrombectomy and virtual reality over the long term too. Looking ahead, we anticipate solid growth in Japan in 2021 and beyond. We additionally achieved solid progress in Europe, Latin America and Asia Pacific in 2020 and anticipate continued growth in 2021. Lastly, I want to talk about the pandemic and how it affected our business. The spike in cases around the holidays and our team's ongoing focus on keeping a safe, working environment for employees had a minor effect on our production. However, provided the virus variants do not alter the current status, we believe we can navigate our production capacity during this period and meet demand. Regarding the effect on our revenue, like most of our peers, we did experience some impact in the first part of the quarter relating to elective cases in the United States and in certain international locations which will have a minor impact on this quarter. Even so, if things keep going along the path we're on now, our expectation is that annual growth for 2021 won't be significantly affected. Now I'll hand things over to Maggie, who will walk everyone through the financial results covering both the quarter and the full year.

Maggie Yuen

executive
#4

Thanks, Adam. Good afternoon, everyone. I'll start by talking about how the recent voluntary recall of JET 7 XTRA FLEX affected us financially, and after that I'll walk through our results for the fourth quarter and for the full year 2020. When the voluntary recall of JET 7 XTRA FLEX was announced on December 15, 2020, the hit to our finances in Q4 came to a $5.8 million decrease in revenue from refunds tied to product returns, plus $12.6 million in charges to cost of sales, mostly for inventory write-offs and the cost of exchanging products. This voluntary recall affected our gross margin by roughly 900 basis points; these numbers reflect the entire anticipated impact on our financial statements from the voluntary recall, since we have accounted for or estimated any returns or exchanges still to come, as the accounting rules require. We don't anticipate any material changes to our financial statements in 2021 — neither a further revenue reduction nor a higher cost-of-sales expense — from any remaining effects of the recall. The fourth quarter financial metrics that follow are non-GAAP financial results, which leave out the voluntary recall's impact, as I described earlier. Just a reminder, fourth quarter GAAP figures and a reconciliation from GAAP to non-GAAP measures are provided. For the quarter that ended December 31, 2020, total non-GAAP revenues came to $172.7 million, up 18.9% as reported and up 17.7% in constant currency versus the fourth quarter of 2019. Our sales mix by geography in the quarter was 70% U.S. and 30% international. U.S. and international both grew sequentially on a reported basis, by 10.5% and 24.4%, respectively, against Q3 2020, or 44.7% in the same period last year. Our year-over-year performance comes from growth across vascular thrombectomy and embolization products, and we also saw strong sequential growth from Lightning 12. Revenue from our neuro business reached $85.6 million in the fourth quarter, up 0.2% as reported and down 1.2% in constant currency versus the same period a year ago. Revenue for JET 7 XTRA FLEX through December 15 was $9 million, or 5.2% of total non-GAAP revenue, excluding the recall's impact. Our U.S. neuro business fell 0.3% as reported on a sequential basis. Our international neuro business rose 30.3% sequentially and 5% as reported versus the same quarter a year ago; these results came from strong performance across Europe, China and Asia-Pacific regions. Our non-GAAP gross margin in the quarter was 65.2% versus 67.6% a year ago, and it improved sequentially from 60.2% in Q3 2020. Our gradual gross margin improvement comes from fixed cost leverage with increased demand and favorable product mix. We continue to invest in direct labor and overhead spending on COVID-19-related safety measures and have made trade-offs in efficiency to ensure employee safety and to support product demand. As we look ahead, we anticipate that gross margin will stay around where it is now, though it may move a bit depending on pricing and the mix of products. Operating expense on a total basis came in at $96.1 million for the quarter, equal to 55.6% of non-GAAP revenue, versus $87.5 million, or 60.3% of revenue, in the comparable quarter last year. R&D spending during Q4 2020 reached $19.5 million, up from $12.9 million in Q4 2019, reflecting our ongoing commitment to funding product development programs. SG&A costs in Q4 2020 totaled $76.6 million, compared with $74.7 million in Q4 2019. The rise in our spending was driven mainly by more headcount and the associated compensation costs, even as we kept up reduced activity in areas like travel and conferences. Non-GAAP operating income for the quarter was $16.6 million, versus operating income of $10.6 million during the same period a year earlier. Now I'll walk through our GAAP results for the full year. Total revenue for full year 2020 came to $560.4 million, up 2.4% on a reported basis and 2.1% in constant currency relative to full year 2019. Our vascular business generated $267.8 million in revenue for full year 2020, a rise of 24.1% reported and 23.9% in constant currency. Revenue from our neuro business for full year 2020 was $292.6 million, down 11.8% reported and 12% in constant currency. Gross profit for the year represented 60.3% of revenues, compared with 68% of revenue for full year 2019. We recorded an operating loss of $38.9 million for the year, against comparable operating income of $47.5 million in 2019. Moving on to cash flow and the balance sheet. During 2020, our inventory balance grew by $67 million, made up primarily of $24 million invested in stocking of REAL System along with $43 million in consignment raw material and finishes, done to support new product launches and rising demand. In the fourth quarter, changes in our go-to-market model led to $18 million of REAL stocking being reclassified on the balance sheet out of property and equipment and into inventory. We closed out the year holding $265 million in cash and cash equivalents and marketable securities, with no debt. At this point I'd like to hand the call over to Jason so he can go over our 2021 guidance.

Jason Mills

executive
#5

Thanks, Maggie, and hello everyone this afternoon. We kicked off 2021 with considerable momentum across our operations. The markets we pursue are sizable. The solutions we offer to doctors are distinctive, and putting patients first continues to be central to who we are. For the entire 2021 fiscal year, we're rolling out revenue guidance between $675 million and $685 million, reflecting growth of 20% to 22% compared with 2020's full-year revenue of $560.4 million. Now, on revenue patterns. We expect first-quarter revenue to come in below our record-breaking Q4 numbers, then rise sequentially across the remaining quarters this year. There are 2 things we want to flag about this guidance. First, January brought disruption to elective procedures due to a renewed wave of COVID infections across the U.S. and elsewhere. In our Q1 results, we believe this will play only a small role. Second, our guidance factors in short-term conditions affecting our neuro thrombectomy segment following the JET 7 XTRA FLEX recall announced in mid-December; even so, we hold positive views regarding both our existing stroke product lineup and our development pipeline, which includes the possibility of establishing a fresh treatment model for stroke intervention. Broadly speaking, in keeping with how we've set guidance previously, this 2021 revenue outlook reflects where we currently stand on our markets, the scheduling of new product introductions and other pertinent considerations. At this point I'll hand things back to Adam for some final comments.

Adam Elsesser

executive
#6

Thank you, Jason. Before we wrap up our prepared comments, I want to start by recognizing how amazing the Penumbra team's efforts have been throughout this difficult period, as they kept ensuring our products remained available to assist so many patients who needed them. The commitment all of you show is remarkable, and working alongside each of you fills me with pride. And last, I'm sure everyone here at Penumbra wants to express appreciation to our physician customers and all of their teams for everything they accomplished across the last 12 months, at times under tremendously difficult conditions, in order to care for their patients. The heroic nature of your work inspires us to keep innovating so we can deliver better and better products, and it has meant an enormous amount to us during this year. Thank you. At this point, we would like to turn the call over to questions. Operator, please go ahead.

Bill Plovanic

analyst
#7

Great. First thing I want to ask — regarding what you shared about cadence and guidance. When you look at that quarter, and strip out the one-time charges, the annual 2021 guidance you've given sits under what the fourth quarter of '20 would be if annualized. So I'm attempting to work out the pluses and minuses here. I get it with neuro and a few of those remarks, and perhaps that isn't a growing line of business, but I'm just attempting to work out whether you anticipate that coming back in a big way? I'm trying to fit all of this together, and it simply comes across as somewhat lower than our expectation would have been.

Jason Mills

executive
#8

Thanks, Bill, for the question. This is Jason. I'll begin, and then Adam can chime in; so like we stated during the prepared remarks, during January we did experience a bit of an impact, similar to what our peer group has encountered with COVID, and we're also simply factoring in the dynamics tied to the neuro thrombectomy business along with the recall; having said that, we're extremely optimistic and confident regarding our business. And as we noted, we anticipate sequential increases as the year moves forward. Adam?

Adam Elsesser

executive
#9

Correct, Bill. When you provide an outlook at the start of the year and you're peering ahead, the aim is to be as precise and prudent as we can. That being said, my view is that for 2021 and naturally past that, this guidance reflects fairly robust expansion for the business. Still, clearly — or rather, what Jason raised regarding the first quarter strikes me as both reasonable and evident. As we move ahead, though, those figures suggest quite solid growth.

Bill Plovanic

analyst
#10

Then, as a quick follow-up to that point. Regarding neurovascular, I believe you mentioned something last year and are touching on it again now — a few of the comments during the prepared remarks concerned the sort of new platform meant to take the place of JET 7 in this neuro space. I was curious whether we might receive slightly more detail regarding what those features and benefits could be, and if that level of specificity isn't possible, perhaps at least some expected timing we ought to keep in mind?

Adam Elsesser

executive
#11

Yes; that's a completely reasonable question. With this question on this call, I won't be breaking any new news, so consider yourself prepared for that. What I can share, though, is that there are 2 distinct items. The first, and we mentioned it during this call, is the refresh to reperfusion catheters, and apart from that, there's what we refer to as this new technology involving a paradigm change. The catheter refresh simply keeps improving them and makes them more trackable. That — which isn't new news. As for the paradigm shift, we've discussed it mostly in general terms, where the aim behind everything we're attempting across all our thrombectomy product lines, especially in stroke, is getting the entire clot out, rather than only a portion of it, and doing so as quickly as possible across every case regardless of where that clot sits. And we believe our new technology can have an impact on that. We'll wait and see, but beyond describing that technology I'm not yet in a position to say more, though we're quite excited about it and want to launch it as soon as we're able.

K. Gong

analyst
#12

Allen here, filling in for Robbie. Let's kick things off with a fast one about Lightning. Clearly, the peripheral portion of the thrombectomy segment will keep performing very strongly, COVID-19 challenges notwithstanding. So as we consider Lightning 7, and the sort of expansion Lightning 12 has delivered for you, since it's entering a space where you already had a very robust arterial footprint, should we view that as more of a moderate upside for the business, and it's not as though you're entering a space where you lacked a strong footprint already? Or might we regard it as delivering as large an effect as Lightning 12 did for the wider franchise?

Adam Elsesser

executive
#13

Yes. That's a genuinely good question. The way we see it, really, is simply in overall figures. Looking at the arterial segment, far more patients undergo intervention — or surgical treatment — for arterial clot than is the case for patients receiving intervention for venous or PE, and we've walked through those figures previously. There are 250,000 — U.S. figures, these are — patients suffering arterial clot who receive treatment via intervention or surgery. Compare that with just over 100,000 on the venous and PE side. So the chance is simply larger. And so that — plus the effect on those patients is quite severe. In many instances — not every one — you're intervening or performing this to ensure a leg or limb can be saved; thus by definition, we believe, over the long term, that, that will deliver a meaningful positive effect on the business but naturally on those patients; so the pace of that, how quickly do people switch to Lightning 7? That remains uncertain. At present, plenty of our customers are achieving excellent results with our existing technology. The obstacle preventing many people from having switched — because, once more, we aren't even treating 10% of these patients. The obstacle for the remaining 90%, frequently, what we've heard physicians say is they don't want to employ as large a catheter as our CAT 8, which is an 8-French system. And so we're now providing a somewhat smaller French size, a 7, yet with nearly all the advantages of a larger catheter. It's just sufficiently smaller, and that's leveraging our new novel technology to maximize the inner diameter. So it's nearly the size of CAT 8 on the inner diameter. But then we combine that with Lightning, which enables a case in which you don't need to fret about blood loss or — and you have sort of the auditorial signals that you're in clot. And those are the factors that I believe will help bring folks who haven't yet tried our system over to try single session. Once more, much of the conversation among these physicians regarding treating in a single session as opposed to lytic therapy across several days has moved to the center of medical debate, largely owing to COVID along with ICU beds and similar factors. So my sense is that we'll achieve genuine success here. Might a number of the doctors who had been employing CAT 8 return to — step down a size? That could happen in particular situations, yet I believe several of them could remain with CAT 8.

Bob Hopkins

analyst
#14

Great. Can you hear me okay?

Adam Elsesser

executive
#15

Yes.

Bob Hopkins

analyst
#16

Great. So a few items. You folks mentioned before that this year you might go deeper into REAL, possibly through an Analyst Day or some kind of event, to add more substance. Will that still take place at some point during this year? And I believe you also stated earlier that the new stroke system would certainly be released at some point in 2021. I just wanted to verify that this remained true.

Adam Elsesser

executive
#17

Let's begin with the stroke area. We have a good degree of confidence. Once more, we don't dictate each regulatory choice regarding when our catheters will be released. We'll hold off and provide a somewhat firmer update regarding the timing of this new paradigm shift once I gain greater confidence and clarity regarding particular dates on the regulatory side. So I don't wish to provide you specific time frames during this call until I possess that certainty. With that said, regarding REAL, we absolutely will present the new technology, the models. As for when, from our perspective, it would be far more beneficial and impactful if this occurred in person, allowing people to experience and view virtual reality. So if it can be arranged during the first half, we'll proceed with that. Should we need to delay somewhat in order to make that happen, we'll find a means to share whatever we can virtually and then follow up in person, and just allow us a little time to work that out. But without a doubt, we will be sharing considerably more in the near term as we get closer, since, as you can see, we're quite enthusiastic about it.

Bob Hopkins

analyst
#18

Right, and following that thought, Adam, how much of a major initiative will this product represent during 2021? I mean, perhaps another way of putting it is that it's implied by the outlook you provided — what sort of impact are you expecting from REAL? Will you be pushing hard on the launch side during this year? Maybe just a bit more detail on what we should anticipate this year regarding that technology.

Adam Elsesser

executive
#19

Yeah. I believe that's a genuinely excellent question. 2021 isn't the year where we anticipate a massive revenue boost from this product. Instead, it's a year during which we have substantial work we intend to accomplish in order to establish the foundation and the groundwork for that revenue growth down the road. However, much of that, I believe, will become even more apparent when we discuss it later and when we sort of lay out both the go-to-market approach and how our thinking has developed regarding this product. Yet once more, the chance to assist an enormous number of people has simply become more evident, and we stay quite enthusiastic. Still, the bulk of our revenue outlook centers on our interventional products.

Bob Hopkins

analyst
#20

Then one final, very brief item regarding the outlook, specifically the neuro portion of it. Is neuro expanding at more than 10% assumed within that outlook? I'm simply attempting to understand roughly how you expect neuro to increase and what portion of the 20% to 22% total growth you're projecting that represents?

Jason Mills

executive
#21

Yes. Bob, this is Jason. I appreciate the question; it's a completely reasonable one. As you're aware, we don't provide guidance broken down to that degree of specificity, so we won't be doing so now. Having said that, when you consider the businesses overall, we're quite enthusiastic about the offerings within the existing portfolios for neuro and vascular, plus the new offerings adding value in each. And we've discussed both the existing and the new during this call. Therefore, I won't provide any ranges for you regarding the 2 businesses, though we have confidence in both that each can add to growth over time.

Lei Huang

analyst
#22

It's Larry — Lei here, calling in on Larry's behalf. Could you expand a bit more on the XTRA FLEX recall, and in particular on the capture rate? You mentioned physicians shifting over to other PEN devices or rival devices and then returning to PEN. Can you put any numbers on that, or add a bit more detail?

Adam Elsesser

executive
#23

Yes. No. Excellent question — and this has been, and I believe still is, somewhat of a shifting situation; so putting a figure on it right now is difficult, since it keeps moving. One thing we had a certain gut feeling about: our ACE68 and our JET 7 standard tip were terrific catheters back when they led the market. Launching JET 7 XTRA FLEX didn't suddenly make them worse catheters; and once you remove JET 7 XTRA FLEX with its tractability and simply stack ACE60 against JET 7 standard tip and against a lot of the other products available, they compare very favorably. They do extremely well. And so I think the character of this — a lot of our physicians want to try new things and confirm how they perform, yet it hasn't caught us off guard, and it has definitely been encouraging for our team to watch so many return to the catheters that have performed so well, that carry enormous clinical data backing their use, and that are genuinely excellent products on their own. So I'd say we're in a fairly solid position — as I noted, we hit a minor back order on JET 7 standard tip, which should clear up soon. So I think we're doing fine; that said, everyone knows how we operate. We never sit back, and we'll keep innovating and can't wait for the new — for some new catheters to arrive later this year.

Lei Huang

analyst
#24

Excellent. If there's room for one more from me, it's about that $1 billion-plus revenue figure for 2023 you mentioned, Adam. With the pandemic and the recall in the picture, what makes you feel at this point that you can actually reach it?

Adam Elsesser

executive
#25

That's a wonderful question, honestly. Where the assurance stems from is the wins we've posted over the past 2 quarters, the expansion across every one of our businesses, but most especially the Lightning series, which truly is only in its opening innings, plus how people have responded to it. Then you factor in a few of the additional offerings we've discussed and highlighted, including on this very call, along with what's in the pipeline, and I'd say that innovation and that habit of continually upgrading from where we start is the source of our belief that we're headed the right way. Still, it's 2 years off. We'll watch how things unfold. Yet I believe you can gather from our prepared remarks and a few of our responses that what we're selling today is doing extremely well and addresses a great many of the problems doctors were hoping to see fixed. I gave a lengthy reply regarding the Lightning 7 matter, partly so it would be clear to everyone that this particular product is somewhat out of the ordinary, correct? You go a bit smaller, though that applies to the inner diameter, making it roughly the same dimension as the CAT 8, or perhaps larger. Even so, you deliver precisely what the physicians asked for while stripping away none of the power — actually, with Lightning you're adding capability. So I'd say those sorts of things, where we pay attention to what our buyers tell us, then refine and bring new ideas forward as quickly as we can, are what let us believe we'll reach that goal.

Jason Mills

executive
#26

One more point I'd tack on here, which Adam brought up during his prepared comments, concerns the overall market environment surrounding all of this. On the product front, I already spoke about how confident and optimistic we feel. Across every segment we're targeting, that market environment looks genuinely favorable — favorable in terms of the patients we've already reached, and even more so for the larger group still to come: 80% in stroke, over 90% in peripheral thrombectomy, plus the entire market ahead of us in virtual reality. So that's the setting, and it's one we're enthusiastic about.

Ryan Zimmerman

analyst
#27

Okay, Adam, let me just pose one thing — I only want to pose one thing. Starting with JET 7 and JET 7 XTRA FLEX, this paradigm shift that you keep mentioning, Adam. I'll frame it differently. What do you see yourself as trying to build on from JET 7 XTRA FLEX that you're addressing, perhaps past the design hurdles you hit with the agency? What still needs work right now in ischemic stroke? And without spoiling whatever you plan to unveil later this year when it's unveiled, what were a few of the problems beyond the ones we perhaps saw in certain reports in the MAUDE database?

Adam Elsesser

executive
#28

Yeah. Thanks, Ryan, for asking. Those 2 matters don't connect, and I believe — it matters a lot to me that you grasp that. So the paradigm — today's paradigm involves making catheters as large as you can so you can, in turn, pull out the maximum amount of clot. And once catheters get larger, keeping them large yet trackable turns into the design hurdle, something JET 7 XTRA FLEX handled quite well, again, provided — when instructions and everything else were obeyed. That paradigm, where each company right now attempts to build larger catheters that track nicely, is the one we're arguing may — could shift, so that race stops being as essential, since you consider another approach to think about clearing all the clot as quickly as you can; so we aren't really — the hurdles, or design considerations rather, behind this new product or new technology truly have nothing to do with JET 7 XTRA FLEX or ACE68 or any other catheters. It's about tackling the root problem, which is how do I in some sense democratize things and widen how many cases succeed. At present, a few physicians can — with particular patients, achieve strong results fast. Other patients lack that sort of result. Our aim is to build a product capable of clearing all the clot as quickly as possible in everyone. And that's kind of the idea. So it's kind of disconnected from JET 7. Whenever we refresh our catheters, what matters for us is getting large catheters to track as quickly as possible — as effectively as we can. That's the paradigm of today. And we'll keep at it until the new technology reaches the market.

Ryan Zimmerman

analyst
#29

Okay, and just to piggyback quickly on Bob's earlier question — I don't know if we'll get any specifics here — but Maggie, I think, mentioned something about a change in how the business is being positioned around REAL. So, comparing that with what you laid out, maybe during the Analyst Day back in '19, what's the right way for us to read those comments about the strategy for REAL?

Adam Elsesser

executive
#30

Yeah, no, Ryan, that's a fair question, and it's among the items we'll be sharing as soon as we're able to. Like Maggie mentioned, it really comes down to how we take this to market. A notable aspect of many projects we've taken on—be it stroke, vascular thrombectomy, or currently REAL—is that they were unprecedented. Back when we entered the stroke space, the notion of guiding a sizable catheter far into the brain to extract a clot was unheard of, which meant there was plenty to solve, study, and refine. REAL follows that same pattern. With additional cases, accumulated know-how, and incoming input, we keep adapting—and I'd say our capacity to develop and tweak things is one of our key advantages. We've examined how we take our products to market and how that approach ought to work, and my sense is that our goals are growing in a way that's both solid and encouraging. What we have here is genuinely capable of serving as a foundation for the whole health care sector, and that's quite a remarkable thing.

Brandon Vazquez

analyst
#31

This is Brandon filling in for Margaret. To start, may I pose something regarding the vascular segment? Could you somehow put a number on how much of an effect COVID had on vascular during 2020? The reason I'm asking is that vascular actually had a really robust year even with a somewhat greater proportion of elective procedures. So what I'm attempting to figure out is whether, as patients return to the funnel, there could be some accumulated vascular cases, and you keep up the momentum you're seeing with Lightning 7 and Lightning 12. Might vascular even speed up further as we go through 2021?

Adam Elsesser

executive
#32

Yeah. That's a genuinely excellent question; so there are actually two components to it. The first component is whether we are observing more patients, so to speak, who have clots as a result of COVID. We definitely observed that around the April-May period, when it was a novel phenomenon, and health care professionals had not yet become sufficiently aware of it and were attempting to catch up. I believe much of that has — medical management for many COVID patients got up to speed quite rapidly, and so I don't believe we are observing any kind of measurable figures, hugely big figures, of additional patients attributable to COVID. Having said that, and I already touched on this today, one of the upsides of COVID and I — the instant I said that, I understood that it came out wrong. I don't intend that as an upside of COVID. But 1 of the 5 products of COVID was the phrase I was searching for is that people had to consider treating many of these patients in single sessions, and that fits squarely with our technology. And that differs from sessions lasting multiple days or needing something like a longer recovery period. And so that, I believe, is broadening many physicians' thinking about the technology we've introduced, and then you factor in the ease of use surrounding Lightning. I think that has definitely helped to steer physicians toward our technology, and I think that phenomenon will remain for some time. I think it will persist because it's somewhat front of mind for many people when they consider the notion of single-session treatment.

Brandon Vazquez

analyst
#33

Understood. Then regarding gross margins, if I caught what Maggie said properly, my understanding is she indicated you generally anticipate gross margins staying roughly consistent or level as we progress through '21. I was simply wondering, first, did I get that right? And second, given a premium attached to Lightning 12 and likely a modest premium on Lightning 7 too, and then once we get beyond COVID, perhaps certain manufacturing efficiencies could begin to fade somewhat. Why — might we begin to observe gross margin growth in the latter portion of '21, perhaps getting near the pre-COVID 2019 figures?

Maggie Yuen

executive
#34

Yes. Appreciate the question. Yes. I did state that, for 2021, gross margin will probably keep sitting at where it currently is and won't revert that swiftly to the pre-COVID gross margin mark. At minimum, not before we're fully clear of the pandemic manufacturing setting and cost structure, which isn't something that flips in a single night. We likely need until the close of 2021 to determine whether the manufacturing environment shifts; we observed a marginally favorable effect on our gross margin because of Lightning, and we intend to expect a comparable pattern moving ahead.

Matt Henriksson

analyst
#35

Matt Henriksson here, sitting in for Joanne. The first thing we want to ask about is stroke. We've discussed at length the new products launching. With stroke protocol, though, 2020 was clearly a slow year. So how are you viewing 2021, given new states and legislation bringing in additional protocols? And in particular, with this new paradigm shift, does that help speed that process up?

Adam Elsesser

executive
#36

Sure. I'll take the second question first. Sadly, I don't believe those 2 things are connected. How a person is treated versus the energy required to bring patients to the right hospital — I think those are, unfortunately, de-linked; it would be good if they were linked. I genuinely lack the visibility I had pre-COVID on the matter of state legislation, partly because state legislators are extremely busy with many other matters. As you're aware, crises are consuming their attention. We do receive — obviously we receive updates from the Get Ahead of Stroke campaign, which the physician society runs. Some states have seen a bit of movement, though it hasn't moved unbelievably quickly. A few things shifted in 2020, so I anticipate some progress in 2021. Still, I believe what drives this near term is the same kind of effort that drove it ahead of the state legislature work, which is people getting back out into their communities and making certain these patients receive treatment. As things edge closer to normalcy, and with many health care workers already vaccinated, we're picking up that they're eager to return and rebuild their practice and head into the community to do so. So I'm optimistic with caution; but once more, I want to stay realistic that in a dynamic such as this, the effort required to push that forward doesn't rise to first priority. And that's what — during my prepared remarks I noted that 2021 experienced that — 2020, experienced that. But I do believe, and here's the part that truly matters, we have far too much evidence that these people ought to be treated. The toll of failing to treat, both for their health and on the financial side, is so substantial that this isn't where the story finishes. We'll keep pushing on this, and we're going to — plenty of people will remain motivated to fuel this growth. It may not come this quarter or the next one, but I do believe it will carry on. I think that's simply — we know too much, and I think it will come to pass. From the company's perspective, and again, I think everybody recognizes this by now, we'll keep growing because our portfolio of products is so broad and spans so many different areas; and stroke clearly isn't the lone factor propelling our growth. Naturally, though, this topic has drawn plenty of inquiries from everyone; our dedication to continuing to break new ground in that space hasn't wavered at all. That said, my honest view is that more time will be needed.

Matt Henriksson

analyst
#37

Got it, that's clear. Now when we look at the R&D line specifically, we saw a decline in the actual dollars spent as well as in the share of revenue from Q3 to Q4. What's the thinking there, starting with how Q4 spending came together? And after that, how should 2021 be viewed? Should we be thinking about something closer to 20% of revenue again, or is roughly 11% to 12% the level we should expect moving ahead?

Maggie Yuen

executive
#38

Sure, I can address that. To begin with, if you recall from the earnings call we held last quarter, we discussed $20 million in one-time R&D costs tied to Lightning 12, which we recorded as a non-GAAP expense. So as we move forward, the percentage of revenue we saw in Q4 is probably the pattern that will continue.

Jee Hamlyn-Harris

executive
#39

Appreciate it, operator. And from everyone on our leadership team, thanks once more for being here with us today and for the interest you've shown in Penumbra. We're glad to bring you up to speed on our first quarter call.

Operator

operator
#40

This concludes today's conference call, and you may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Penumbra, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Penumbra, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Penumbra, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.